These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 28407436)

  • 21. Immunologic and virological response to ART among HIV infected individuals at a tertiary hospital in Ghana.
    Obiri-Yeboah D; Pappoe F; Baidoo I; Arthur F; Hayfron-Benjamin A; Essien-Baidoo S; Kwakye-Nuako G; Ayisi Addo S
    BMC Infect Dis; 2018 May; 18(1):230. PubMed ID: 29783953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Which adherence measure - self-report, clinician recorded or pharmacy refill - is best able to predict detectable viral load in a public ART programme without routine plasma viral load monitoring?
    Mekuria LA; Prins JM; Yalew AW; Sprangers MA; Nieuwkerk PT
    Trop Med Int Health; 2016 Jul; 21(7):856-69. PubMed ID: 27118068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using a composite adherence tool to assess ART response and risk factors of poor adherence in pregnant and breastfeeding HIV-positive Cameroonian women at 6 and 12 months after initiating option B.
    Atanga PN; Ndetan HT; Fon PN; Meriki HD; Muffih TP; Achidi EA; Hoelscher M; Kroidl A
    BMC Pregnancy Childbirth; 2018 Oct; 18(1):418. PubMed ID: 30359239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Universal test and treat is not associated with sub-optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial.
    Iwuji C; McGrath N; Calmy A; Dabis F; Pillay D; Newell ML; Baisley K; Porter K
    J Int AIDS Soc; 2018 Jun; 21(6):e25112. PubMed ID: 29890048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
    Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
    HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings.
    Kiertiburanakul S; Boettiger D; Ng OT; Van Kinh N; Merati TP; Avihingsanon A; Wong WW; Lee MP; Chaiwarith R; Kamarulzaman A; Kantipong P; Zhang F; Choi JY; Kumarasamy N; Ditangco R; Cuong DD; Oka S; Sim BLH; Ratanasuwan W; Ly PS; Yunihastuti E; Pujari S; Ross JL; Law M; Sungkanuparph S;
    AIDS Res Ther; 2017; 14():27. PubMed ID: 28484509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015.
    Bulage L; Ssewanyana I; Nankabirwa V; Nsubuga F; Kihembo C; Pande G; Ario AR; Matovu JK; Wanyenze RK; Kiyaga C
    BMC Infect Dis; 2017 May; 17(1):326. PubMed ID: 28468608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study.
    Nsanzimana S; Semakula M; Ndahindwa V; Remera E; Sebuhoro D; Uwizihiwe JP; Ford N; Tanner M; Kanters S; Mills EJ; Bucher HC
    BMC Infect Dis; 2019 Apr; 19(1):312. PubMed ID: 30953449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiretroviral treatment failure and associated factors among HIV patients on first-line antiretroviral treatment in Sekota, northeast Ethiopia.
    Nega J; Taye S; Million Y; Rodrigo C; Eshetie S
    AIDS Res Ther; 2020 Jul; 17(1):39. PubMed ID: 32650796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces.
    Tran DA; Wilson DP; Shakeshaft A; Ngo AD; Doran C; Zhang L
    Sex Transm Infect; 2014 Nov; 90(7):538-44. PubMed ID: 24619575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with the failure of first and second-line antiretroviral therapies therapy, a case control study in Cambodian HIV-1 infected children.
    Barennes H; Virak K; Rouet F; Buisson Y; Strobel M; Vibol U
    BMC Res Notes; 2016 Feb; 9():69. PubMed ID: 26850410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth in HIV-infected children on long-term antiretroviral therapy.
    Feucht UD; Van Bruwaene L; Becker PJ; Kruger M
    Trop Med Int Health; 2016 May; 21(5):619-29. PubMed ID: 26914715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland.
    Jobanputra K; Parker LA; Azih C; Okello V; Maphalala G; Kershberger B; Khogali M; Lujan J; Antierens A; Teck R; Ellman T; Kosgei R; Reid T
    PLoS One; 2015; 10(2):e0116144. PubMed ID: 25695494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral treatment outcome in HIV-1-infected patients routinely followed up in capital cities and remote areas of Senegal, Mali and Guinea-Conakry.
    Diouara AA; Ndiaye HD; Guindo I; Bangoura N; Cissé M; Edmond T; Bougoudogo F; Mboup S; Peeters M; Ayouba A; Kane NC
    J Int AIDS Soc; 2014; 17(1):19315. PubMed ID: 25527333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
    Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
    J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement in mortality and retention among adult HIV-infected patients in the first 12 months of antiretroviral therapy in Dodoma urban district, Tanzania.
    Tweve EN; Kayabu D; Nassari NO; Todd J
    Trop Med Int Health; 2015 Jun; 20(6):791-6. PubMed ID: 25706518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM).
    Liégeois F; Eymard-Duvernay S; Boyer S; Maradan G; Kouanfack C; Domyeum J; Boyer V; Mpoudi-Ngolé E; Spire B; Delaporte E; Vidal L; Kuaban C; Laurent C;
    HIV Med; 2019 Jan; 20(1):38-46. PubMed ID: 30362279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
    Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.